Literature DB >> 16925713

Case of recurrent macular haemorrhage after removal of a sub-internal limiting membrane haematoma secondary to retinal artery macroaneurysm.

Kazuki Hotta, Junko Hotta.   

Abstract

The authors report the case of an 80-year-old man with sub-internal limiting membrane haematoma secondary to retinal artery macroaneurysm in the right eye. Corrected visual acuity was 6/60 in the right eye. Vitreous surgery was performed. The internal limiting membrane over the haematoma was removed by pulling with a soft-tipped extrusion cannula, and then the haematoma was removed with a vitreous cutter. One month post surgery vision had improved to 6/9. Two months post surgery, however, the same macroaneurysm ruptured again, and vision decreased to 6/60. Clinicians should be aware that recurrent macular haemorrhage may occur after removal of sub-internal limiting membrane haematoma secondary to macroaneurysm.

Entities:  

Mesh:

Year:  2006        PMID: 16925713     DOI: 10.1111/j.1442-9071.2006.01286.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  3 in total

1.  Sub-inner limiting membrane haemorrhage: causes and treatment with vitrectomy.

Authors:  Karolien De Maeyer; Rita Van Ginderdeuren; Laurence Postelmans; Peter Stalmans; Joachim Van Calster
Journal:  Br J Ophthalmol       Date:  2007-01-17       Impact factor: 4.638

2.  Visual outcome after vitreous, sub-internal limiting membrane, and/or submacular hemorrhage removal associated with ruptured retinal arterial macroaneurysms.

Authors:  Hideo Nakamura; Kazuhisa Hayakawa; Shoichi Sawaguchi; Takeshi Gaja; Noriyoshi Nagamine; Kodo Medoruma
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-12-11       Impact factor: 3.117

3.  Influence of bevacizumab therapy and intraretinal hemorrhage in long-term outcomes of hemorrhagic retinal arterial macroaneurysm.

Authors:  Jae Hui Kim; Jong Woo Kim; Chul Gu Kim; Young Ju Lew; Han Joo Cho
Journal:  Sci Rep       Date:  2021-07-09       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.